Human-Relevant Non-Animal Methodologies (NAMs)
Specialised Models Series: **Neurological & Psychiatric**

Psychiatric & Mental Health Models

Reference 3.2 in Full Scope Roadmap

Version 1.0 | June 2026 Edition
Compiled for the Alliance for Cruelty Free Science by Georgina Rednall
Prepared for Academic Leadership, Animal Welfare & Ethical Review Bodies (AWERB), and Principal Investigators

Legal & Scientific Imperative for Universities

Section 2A of the *Animals (Scientific Procedures) Act 1986* imposes a statutory duty on the Secretary of State to ensure compliance with the principles of replacement, reduction, and refinement. The principle of replacement requires that, wherever a scientifically satisfactory method or testing strategy not entailing the use of protected animals is available, it must be used to replace the use of a regulated procedure.

Traditional neurobiology and behavioural workflows rely heavily on legacy *in vivo* models—such as transgenic rodent lines for psychiatric conditions, or stress-induction assays like forced swim tests for depression. These platforms suffer from severe translational limitations. These limitations are evident in the following critical disparities:

- **Cognitive and Psychosocial Divergence:** Animals lack the high-level cognitive, linguistic, and complex psychosocial networks characteristic of the human brain. Consequently, rodent behavioural assays fail to capture the subjective emotional and cognitive nuances of psychiatric disorders.

- **Neurocircuitry and Synaptic Architecture:** Species-specific differences in synaptic pruning kinetics and complex neurocircuitry mean that the neural substrates of human mood, anxiety, and psychosis are fundamentally distinct from those observed in standard animal models.

- **Molecular and Cellular Mismatch:** Human-restricted protein isoforms and distinct neuroinflammatory pathways drive the pathogenesis of mental health conditions. Standard models fail to mimic the human cellular environment, leading to high failure rates in identifying effective therapeutic targets.
- **Severity of Behavioural Paradigms:** Stress-induction and forced behavioural assays often involve protocols that induce significant fear, helplessness, and psychological distress in animals, providing a major ethical and regulatory impetus to prioritise replacement.

Accelerating the adoption of human-relevant Non-Animal Methodologies (NAMs)—spanning microfluidic neurovascular barrier chips, patient-derived brain organoids, multi-regional assembloids, and neurocomputational digital twins—is both a scientific imperative to solve the clinical translation crisis and a legal mandate for UK universities under ASPA 1986.

Landmark Regulatory & Scientific Momentum

Significant progress has been made in the development and application of human-relevant Neurological/Brain/CNS NAMs, moving research away from outdated legacy models and toward high-fidelity, predictive platforms.

3.1 Core Neurological & CNS Models

- **Human Neurovascular Unit (NVU) & BBB-on-Chip**: Recapitulates the selective permeability, shear stress dynamics, and multi-lineage cellular interactions (endothelial cells, pericytes, and astrocytes) of the human blood-brain barrier.
- **Brain Spheres & Neurospheres**: Utilise 3D neural cell aggregates to study proliferation, migration, and early network formation in neurodevelopmental research and regulatory neurotoxicity screening.
- **Patient-Derived iPSC Brain Organoids**: Recreate human-specific cell-type ratios, structural layering, and early neural pathology to model localised neurodegenerative progression (e.g., Alzheimer's tau pathology or Parkinson's alpha-synuclein aggregation) without animal genetic modifications.

3.2 Psychiatric/Mental Health Models

This section covers loop circuit dynamics, synaptic pruning mechanics, and patient-derived neuroimmune models that recreate human-specific neuropsychiatric phenotypes and synaptic connectivity.

- **Assembled Neurological & Psychiatric "Assembloids"**: Utilise induced pluripotent stem cells (iPSCs) to generate self-organising 3D brain tissue that mimics human cortical layering, regional brain architecture, and functional synaptic network activity. These fuse distinct regional organoids (e.g., cortical and striatal) to map abnormal pathway connectivity seen in schizophrenia and bipolar disorder.
- **Microfluidic Synaptic Pruning-on-Chip**: Faithfully recapitulates the selective microglia-mediated synaptic engulfment and multi-lineage cellular interactions (neurons, astrocytes, and microglia) involved in neurodevelopmental conditions like Autism Spectrum Disorder (ASD).
- **In Silico Neuropharmacological Modelling**: Leverages structural molecular biology and machine learning to map neurotransmitter receptor binding profiles, forecast drug-induced receptor internalisation mechanics, and simulate network-level synaptic dysfunction under different chemical phenotypes.

Core Specialised Neurological & Psychiatric Platforms



Figure 1: Core Specialised Neurological & Psychiatric Platforms — Microfluidic neurovascular unit (BBB-on-Chip) displaying human brain endothelium, pericytes, and astrocyte end-feet interactions under physiological fluid shear stress *(left)*; fused multi-regional psychiatric "assembloid" system modelling targeted loop projections (corticostriatal-thalamic pathways) and active microglia-mediated synaptic pruning *(centre)*; and a high-throughput multi-electrode array (MEA) microplate tracking electrophysiological synchrony metrics and functional network-level spike/burst firing patterns *(right)*.

Table 1: Specialised Biological & Tissue-Engineered (In Vitro) CNS Platforms

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
Multi-Region Pathway-on-Chip	Microfluidic platforms hosting human primary or iPSC-derived neurons isolated in micro-channels to evaluate directional neurite outgrowth.	Modeling loop circuit vulnerabilities (e.g., thalamocortical or corticostriatal dysregulation) implicated in Schizophrenia, OCD, and ADHD.	Provides a human-relevant alternative to behavioral rodent models that rely on artificial stress induction or physical distress.
Synaptic Pruning & Neuroimmune Axis Platforms	Co-cultures of human neurons, astrocytes, and microglia in microphysiological systems to track cell-cell signalling.	Mapping abnormal microglia-mediated synaptic engulfment, localised cytokine profiles, and neuroimmune markers in Autism Spectrum Disorder (ASD).	Replaces invasive animal tissue harvesting and post-mortem histology used to track synaptic density and glial activity.
Electrophysiological Synchrony MEA Microplates	Human iPSC-derived neural networks coupled to multi-electrode arrays to track population-level neural synchrony indices.	Real-time screening of psychotropic drug safety, assessing compound-induced changes in firing rates, bursting frequencies, and network synchrony.	Eliminates the need for surgical intracranial electrode implantation and telemetry monitoring in live animals.

Cross-Cutting & Enabling Platforms for Neurological & Psychiatric Research

These platforms support multiple neurological and psychiatric research areas and are widely applicable across neurotransmitter profiling, high-content phenotypic screening pipelines, and targeted small-molecule therapies. While specialised models focus on localised circuitry or neuroimmune interactions, these enabling platforms are essential for validating high-maturity NAMs and ensuring they meet the high standards required for regulatory-accepted, "fit-for-purpose" research.



Figure 2: Cross-Cutting & Enabling Platforms for Neurological & Psychiatric Research — This figure illustrates three integrated, high-maturity NAM platforms: AI-driven molecular docking for blood-brain barrier penetration analysis (left), multi-scale computational digital twins for simulating circuit degeneration and virtual drug testing (centre), and Quantitative Adverse Outcome Pathway (qAOP) networks for predictive toxicology and neuro-risk assessment (right).

Table 2: Genetic, Computational & Framework-Driven Platforms

Platform / Model	Description	Key Applications	Benefits for Universities & 3Rs
AlphaFold & AI-Driven Structural Neurological Modelling	Computational protein-structure prediction tools used to map 3D conformations of human-specific receptor complexes and misfolded protein aggregates.	Modelling specific tau configurations, amyloid-beta plaques, and alpha-synuclein binding sites; optimising blood-brain barrier transporter target configurations.	Replaces animal-based antibody generation and structural extraction methods that rely on harvesting animal brain tissues.
In Silico Neural Circuit Digital Twins	Mathematical and kinetic computational models that simulate whole-brain or regional neural circuit signaling and synaptic decay over time.	Forecasting long-term disease progression, network-level drug effects, and optimising clinical trial patient selection criteria.	Holistic systems biology tool; ideal for guiding experimental parameters and replacing multi-year longitudinal non-human primate studies.
qAOP-Integrated Screeners	Quantitative Adverse Outcome Pathway (qAOP) networks linking molecular initiation events to structural and functional alterations.	Regulatory-grade safety and efficacy screening for neurodevelopmental toxicity (DNT), environmental toxicity profiling, and drug-induced seizures.	Aligns perfectly with Home Office / ASRU standards for regulatory acceptance and "fit-for-purpose" safety profiling.

Regulatory Software & Strategy Frameworks

- Regulatory acceptance of NAMs—referred to as "fit-for-purpose qualification"—is not a one-size-fits-all process. Researchers should utilise the following frameworks to ensure their computational and biological strategies align with the *Animals (Scientific Procedures) Act 1986* and industry best practices:
- **Context of Use (COU) Documentation:** Before deploying models, clearly define the specific scientific question the model is intended to address. This is critical for demonstrating that the NAM is reliable and suitable for its intended regulatory purpose.
- **Technical Characterisation:** Maintain comprehensive Standard Operating Procedures (SOPs) and study plans for both the biological NAM and any software used to analyse its output. This transparency is vital for successful project licence applications.
- **Early Regulatory Engagement:** Leverage institutional or external regulatory support to track "fit-for-purpose" milestones. Early engagement with the Home Office/ASRU is strongly encouraged to test the acceptability of a computational or NAM-based approach before full project submission.
- **Weight-of-Evidence (WoE) Frameworks:** Use integrated digital dashboards to aggregate data from both *in vitro* (NAM) and *in silico* (computational) sources. Building a strong "weight-of-evidence" argument is the most effective way to strengthen Replacement justifications when moving away from traditional animal models.

Skills • Training, and Capacity Building

Successful adoption of high-maturity Non-Animal Methodologies (NAMs) requires a strategic shift in workforce development. To ensure the long-term success of the platforms outlined in this series, universities should prioritise the following training initiatives to build institutional capacity:

- **Integrated Neurobiology & Microengineering:** Training programmes should bridge the gap between bench-top cellular biology, fluidic microengineering, and complex electrophysiology data analysis. Researchers require dual proficiency in maintaining long-term fluidic circuit barriers and leveraging the computational pipelines necessary to interpret high-density microelectrode array data.
- **Regulatory Competency:** Staff should receive formal training on "Fit-for-Purpose" qualification and the specific regulatory expectations of the Home Office/ASRU. This includes understanding how to document evidence for the 3Rs within formal project licence applications to ensure they meet legal standards.
- **Technological Literacy:** Skills in microfluidic device troubleshooting, primary stem-cell tissue differentiation, brain organoid maintenance, and AI-driven structural computational modelling are increasingly critical for modern neurobiology research. Universities should facilitate internal workshops or establish external partnerships to provide PhD students and postdoctoral fellows with hands-on experience in these specialised tools.
- **Ethics & Translation:** Education should focus on the scientific imperative of human-relevant research, emphasising why NAMs provide more predictive insights for clinical outcomes than traditional rodent models. This fosters a culture of excellence and ethical research design that is fully aligned with modern international standards.

Table 3: Skills • Training, and Capacity Building

Capability Domain	Focus Area	Impact on 3Rs/Replacement
Technical	iPSC-derived assemblobid generation & microfluidics	Replaces stress-induction and behavioural animal models
Computational	Neuro-circuit modelling & digital twin simulation	Bypasses invasive and distressing animal psych-assays
Regulatory	Fit-for-Purpose validation for complex brain systems	Streamlines approval for advanced human-centric platforms
Bioinformatics	Synaptic-connectivity & pathway mapping	Eliminates animal-based brain lesion/ circuit studies

Strategic Note: This investment in human expertise is a key component of a robust, future-proof institutional roadmap, demonstrating to regulators that the institution is committed to the safe and effective operation of high-maturity NAMs.

Clinical Translation Case Studies

Case Study 1: Human Blood-Brain Barrier-on-Chip Correcting Rodent Transport Anomalies (3.1)

- **Background:** A major pharmaceutical candidate designed to clear amyloid plaques showed high brain penetration in mouse models via receptor-mediated transport. However, it completely failed in early human clinical trials due to zero blood-brain barrier penetration, costing millions in wasted development.
- **The Paradigm Shift:** A university neurobiology lab re-evaluated the failed therapeutic using a microfluidic human neurovascular unit chip. The human-relevant platform correctly predicted the clinical failure, demonstrating that the specific target transporter is expressed differently in human brain endothelium compared to rodents.
- **The Methodology:** Researchers used the microfluidic platform to measure real-time human endothelial permeability, receptor binding dynamics, and astrocyte-mediated transport kinetics. The human chip accurately mirrored the clinical zero-penetration data, proving that animal transport profiles were false-positive indicators.
- **University & Legal Takeaway:** These results offer compelling non-animal evidence to support Project Licence applications, illustrating a clear methodology for replacing animal pharmacokinetic models under ASPA 1986 requirements.

Case Study 2: iPSC-Derived Cortical Organoids Validating Neurodevelopmental Targets (3.2)

- **Background:** Developing an effective therapeutic to halt abnormal synaptic pruning in Autism Spectrum Disorders (ASD) typically requires breeding, aging, and sacrificing hundreds of transgenic rodents over multi-year timelines.
- **The Paradigm Shift:** Academic research groups utilised patient-derived cortical organoids harbouring specific familial mutations to evaluate the drug's efficacy and mechanism of action, completely removing animal cohorts from the discovery pipeline.
- **The Methodology:** Computational models were first used to optimise the small molecule's docking profile. The compound was then applied directly to 3D human brain organoids over a 12-week timeline. Researchers successfully quantified reduced microglial engulfment, restored synaptic density, and preserved network synchrony using high-resolution imaging and multi-omics analysis.
- **University & Legal Takeaway:** Demonstrates that high-fidelity human *in vitro* organoid models can serve as primary efficacy screens, providing solid legal justification to the Home Office that animal testing was completely unnecessary for this mechanistic validation pipeline.

Executive Summary & Compliance Dashboard

Executive Summary

Traditional psychiatric research has relied on legacy *in vivo* models, including stress-induction paradigms and transgenic rodent lines, which fail to capture the high-level cognitive, linguistic, and complex psychosocial networks unique to the human brain. These models present significant translational barriers due to species-specific differences in synaptic architecture, neurocircuitry, and neuroinflammatory pathways. This roadmap outlines a transition to high-fidelity, human-relevant NAMs (assembloids, microfluidic synaptic-on-chip systems, and neurocomputational digital twins), facilitating a research paradigm that is more accurate, ethically sound, and fully aligned with the ASPA 1986 mandate to move away from high-severity animal behavioural procedures.

Compliance Dashboard

Focus Area	Primary Animal Model	NAM Replacement Technology	ASPA 1986 Status
Psychiatric & Mental Health	Rodent stress/ behavioural assays	Brain Assembloids & Synaptic-on-Chip	High

See Appendix: Animal-Free Matrix for the long term strategic implementation roadmap

Maturity Matrix

Phase 1 (Exploratory): Audit current animal use in stress-induction and behavioural research.

Phase 2 (Pilot): Integrate iPSC-derived assembloids and microfluidic synaptic pruning platforms into research pipelines.

Phase 3 (Integration): Implement neurocomputational digital twins to model multi-regional circuit dynamics.

Phase 4 (Standardisation): Replace 100% of high-severity stress and fear-based animal behavioural assays with qualified human-relevant NAMs.

Final Compliance Statement

All proposed models satisfy the Section 2A statutory duty of ASPA 1986. By adopting these methodologies, the institution positions itself at the forefront of the global transition toward human-centric, cruelty-free medical science.

Integration Context: Roadmap Conclusion

The modules detailed in this roadmap—from the fundamental psychiatric and mental health models explored in this series to the broader neurobiological frameworks established previously—demonstrate that replacement is an integrated institutional strategy. By mapping these specialised NAM-based psychiatric platforms into a unified regulatory framework, the institution moves decisively toward a standardised, human-centric research paradigm. This systemic integration is the essential prerequisite for fulfilling the ASPA 1986 statutory duty, ensuring all research is scientifically accurate, ethically aligned, and regulatory compliant.

Appendix: Animal-Free Maturity Matrix

Psychiatric & Mental Health Research Roadmap

This matrix maps the progression of psychiatric and mental health research platforms from legacy *in vivo* reliance to human-relevant, animal-free methodologies, focusing on the specific needs of psychiatric modelling.

Technology Platform	Phase 1: Exploration	Phase 2: Integration	Phase 3: Validation	Phase 4: Adoption
Brain Assembloids	Circuit connectivity mapping.	Standardised SOP development.	Multi-lab validation; trait modeling.	Regulatory-standardized use.
Neuro-on-a-Chip	Microfluidic architecture design.	Signaling pathway testing.	Integration into WoE frameworks.	High-throughput drug screening.
In Silico Twins	Computational network design.	AI-driven neuro-modelling.	Predictive longitudinal modeling.	Primary tool for target discovery.
AI Behavioural Models	Cognitive interaction modeling.	Kinetic synaptic simulations.	Data benchmarking vs. legacy models.	Core standard for efficacy testing.

Implementation & Compliance Framework

To ensure institutional adherence to the **Animals (Scientific Procedures) Act 1986 (ASPA 1986)**, the following five-phase roadmap must be applied to all research projects.

Phase 1: Gap Analysis & Resource Audit
Audit current protocols to identify legacy projects suitable for NAM transition.
Assess institutional capacity for iPSC-derived technologies and high-performance computing.

Phase 2: Standardised SOP Development
Develop rigorous SOPs for assembloid fabrication and "on-a-chip" systems to ensure intra-laboratory reproducibility.
Replace traditional behavioural assays with validated AI-driven kinetic simulations.

Phase 3: Weight-of-Evidence (WoE) Dossier Construction
Aggregate performance data from multi-organ simulations and epitope mapping.
Benchmark NAM outputs against historical legacy data to prove "fit-for-purpose" status.

Phase 4: Regulatory Alignment & Dashboard Tracking
Use a **Compliance Dashboard** to report project milestones directly to the Animals in Science Regulation Unit (ASRU).
Leverage this documentation to justify the reduction or total cessation of animal procedures.

Phase 5: Continuous Capability Building
Invest in specialised staff training for digital twin and synaptic chip operation.

Maintain this document as a "living instrument," updating the matrix as emerging technologies reach maturity.